Bristol Myers Squibb Acquires Orbital Therapeutics to Expand Cell Therapy Portfolio
Bristol Myers Squibb has acquired Orbital Therapeutics for $1.5 billion to expand its involvement in cell therapies, particularly CAR-T treatments.
Tag
Cell Therapies
All articles tagged with #cell therapies
Unveiling the Mysteries of the Dopaminergic System: Insights from Organoid and Assembloid Models
Researchers have developed an organoid model that replicates the structure, connectivity, and functionality of the human dopaminergic system, shedding light on Parkinson's disease and the long-term effects of chronic cocaine use. The model shows promise in improving cell therapies for Parkinson's disease and provides insights into addiction research.
Eli Lilly Acquires Sigilon Therapeutics, Expanding Diabetes Treatments
Pharmaceutical company Eli Lilly has announced its plans to acquire the remaining shares of Sigilon Therapeutics, a company specializing in experimental cell therapies for diabetes patients. The deal, valued at $34.6 million in upfront cash, will provide Lilly with access to Sigilon's proprietary cell therapy candidate for treating type 1 diabetes. The acquisition is expected to close in the third quarter of 2023.
Eli Lilly's Acquisition of Sigilon Therapeutics Boosts Diabetes Treatment Portfolio
Eli Lilly and Co announced its plans to acquire the remaining shares of Sigilon Therapeutics to expand its diabetes treatments. The deal, valued at $34.6 million in upfront cash, will give Lilly access to Sigilon's proprietary cell therapy candidate for type 1 diabetes. Sigilon shareholders may receive an additional $111.64 per share based on certain milestones. The acquisition is expected to close in Q3 2023.
Prime Medicine CEO eyes CAR-T therapy for autoimmune diseases.
Prime Medicine is considering developing cell therapies for autoimmune diseases and may seek a partner for cancer cell therapies. The biotech would join a growing list of groups creating CAR-T therapies for autoimmune conditions like lupus, which were first developed for cancer and have been transformative for patients who can access them.